日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

定量 HER2 组织和血浆分析可预测曲妥珠单抗 deruxtecan 对乳腺癌的活性。

Tarantino Paolo, Kim Se-Eun, Hughes Melissa E, Kusmick Ross J, Smith Kalie, Brasó-Maristany Fara, Nyein Chan Nay Nwe, Paré Brunet Laia, Alder Laura, Garcia-Cortes Diana, Gomez Tejeda Zanudo Jorge, Pereslete Alyssa M, Noteware Laura, Moore Heather, Van Swearingen Amanda E D, Li Tianyu, Gupta Hersh, D'Amico Olivia, Martini Alba, Morganti Stefania, Spindel Jennifer, Cook Charmaine, McLaughlin Christine, Dvir Kathrin, Garrido-Castro Ana C, Sammons Sarah, Files Janet, Sendrick Kerry, Buck Simone, Dillon Deborah, Jeselsohn Rinath, Li Yvonne Y, Cherniack Andrew D, LoRusso Patricia, Lustberg Maryam, Vega-León Rosario, Pardo Francisco, Davis Justin, Mueller Claudius, Corgiat Brian, Curigliano Giuseppe, Anders Carey K, Petricoin Emanuel F, Rimm David L, Prat Aleix, Tayob Nabihah, Lin Nancy U, Tolaney Sara M

When herds overgraze: the cost of conformity in oncology drug development

过度放牧:肿瘤药物研发中墨守成规的代价

Liu, Jia; LoRusso, Patricia

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

Autogene cevumeran联合或不联合atezolizumab治疗晚期实体瘤:一项I期试验

Lopez, Juanita; Powles, Thomas; Braiteh, Fadi; Siu, Lillian L; LoRusso, Patricia; Friedman, Claire F; Balmanoukian, Ani S; Gordon, Michael; Yachnin, Jeffrey; Rottey, Sylvie; Karydis, Ioannis; Fisher, George A; Schmidt, Marcus; Schuler, Martin; Sullivan, Ryan J; Burris, Howard A; Galvao, Vladimir; Henick, Brian S; Dirix, Luc; Jaeger, Dirk; Ott, Patrick A; Wong, Kit Man; Jerusalem, Guy; Schiza, Aglaia; Fong, Lawrence; Steeghs, Neeltje; Leidner, Rom S; Rittmeyer, Achim; Laurie, Scott A; Gort, Eelke; Aljumaily, Raid; Melero, Ignacio; Sabado, Rachel L; Rhee, Ina; Mancuso, Michael R; Muller, Lars; Fine, Gregg D; Yadav, Mahesh; Kim, Leesun; Leveque, Vincent J P; Robert, Alberto; Darwish, Martine; Qi, Ting; Zhu, Jiawen; Zhang, Jingbin; Twomey, Patrick; Rao, Gautham K; Low, Donald W; Petry, Chris; Lo, Amy A; Schartner, Jill M; Delamarre, Lélia; Mellman, Ira; Löwer, Martin; Müller, Felicitas; Derhovanessian, Evelyna; Cortini, Andrea; Manning, Luisa; Maurus, Daniel; Brachtendorf, Sebastian; Lörks, Verena; Omokoko, Tana; Godehardt, Eva; Becker, Dirk; Hawner, Christine; Wallrapp, Christine; Albrecht, Christian; Kröner, Christoph; Tadmor, Arbel D; Diekmann, Jan; Vormehr, Mathias; Jork, Anette; Paruzynski, Anna; Lang, Maren; Blake, Jonathon; Hennig, Oliver; Kuhn, Andreas N; Sahin, Ugur; Türeci, Özlem; Camidge, D Ross

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Divarasib 单药治疗 KRAS G12C 阳性非小细胞肺癌患者:一项 I 期研究的长期随访

Sacher, Adrian G; Miller, Wilson H Jr; Patel, Manish R; Paz-Ares, Luis; Santoro, Armando; Ahn, Myung-Ju; Dziadziuszko, Rafal; Freres, Pierre; Luo, Jia; Bowyer, Samantha; Desai, Jayesh; Markman, Ben; De Miguel, Maria; Deva, Sanjeev; Falcon, Alejandro; Alonso, Guzman; Guedes, João Daniel; Kim, Se Hyun; Krebs, Matthew G; Laurie, Scott A; Massarelli, Erminia; Medina, Laura; Prenen, Hans; Amatu, Alessio; Van Dongen, Marloes; Choi, Yoonha; Hou, Xuefeng; Qi, Ting; Lin, Mark T; Koli, Kalpesh; Mayo, Mariah C; Yau, Kenneth K; Royer-Joo, Stephanie; Chang, Julie; Jun, Tomi; Dharia, Neekesh V; Schutzman, Jennifer L; Lorusso, Patricia

High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties

MGMT高表达可识别具有独特基因组特征和免疫逃逸特性的侵袭性结直肠癌。

Zhang, Janie Yue; Rajendran, Barani Kumar; Desai, Shruti S; Gibson, Joanna; DiPalermo, Jassim; LoRusso, Patricia; Kong, Yong; Zhao, Hongyu; Cecchini, Michael; Schalper, Kurt A

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors

STING激动剂E7766治疗晚期实体瘤的I期剂量递增和药效学研究

Luke, Jason J; Pinato, David J; Juric, Dejan; LoRusso, Patricia; Hosein, Peter J; Desai, Anupam M; Haddad, Robert; de Miguel, María; Cervantes, Andrés; Kim, Won Seog; Marabelle, Aurélien; Zhang, Yan; Rong, Yuanxin; Yuan, Xiaobin; Champiat, Stéphane

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer

用于治疗铂耐药性卵巢癌的髓系靶向抗体 PY159 和 PY314

Yeku, Oladapo O; Barve, Minal; Tan, Winston W; Wang, Judy; Patnaik, Amita; LoRusso, Patricia; Richardson, Debra L; Naqash, Abdul Rafeh; Lynam, Sarah K; Fu, Siqing; Gordon, Michael; Hubbard, Joleen; Kummar, Shivaani; Kyriakopoulos, Christos; Dowlati, Afshin; Chamberlain, Marc; Winer, Ira

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B

PD-1 和 TIM-3 联合靶向治疗局部晚期或转移性非小细胞肺癌患者:AMBER 第二部分 B

Davar, Diwakar; Eroglu, Zeynep; Milhem, Mohammed; Becerra, Carlos; Gutierrez, Martin; Ribas, Antoni; Di Pace, Brian; Wang, Tianli; Zhang, Hailei; Ghosh, Srimoyee; Yanamandra, Niranjan; Borgovan, Theo; Srivats, Shyam; Waszak, Angela; Dhar, Arindam; LoRusso, Patricia

First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

INCAGN01876(一种糖皮质激素诱导的肿瘤坏死因子受体激动剂)在晚期或转移性实体瘤患者中的首次人体I/II期研究

Hamid, Omid; Cardin, Dana B; Hodi, F Stephen; LoRusso, Patricia; Merghoub, Taha; Zappasodi, Roberta; Maniyar, Rachana; Janik, John E; van der Velden, Maikel V W; Zhou, Feng; Dong, Zhiwan; Chen, Xuejun; Harding, James J

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials

FDA-AACR肿瘤药物产品剂量优化策略:注册试验的最佳剂量选择

Shord, Stacy S; Chen, Cong; Jin, Jin Y; Van Wart, Scott; Martin, Sarah K; Davidson, Brad A; Liu, Jiang; LoRusso, Patricia M; Oxnard, Geoffrey R